Company: APXT
Filing Date: 2025-10-01
Form Type: S-1/A
Source: 0001213900-25-094793
Chunk: 378

Company: Apex Treasury Corp
Filing Date: 2025-10-01
Form: S-1/A
Chunk 378
---
 founder shares would represent 25% of the outstanding shares after this offering. Up to 1,250,000 of these shares will be surrendered for no consideration depending on the extent to which the underwriters’ over -allotmentis exercised.

II-1

Our sponsor is an accredited investor for purposes of Rule 501 of Regulation D. Each of the equity holders in our sponsor is an accredited investor under Rule 501 of Regulation D. The sole business of our sponsor is to act as the company’s sponsor in connection with this offering. The limited liability company agreement of our sponsor provides that its membership interests may only be transferred to our officers or directors or other persons affiliated with our sponsor, or in connection with estate planning transfers. Our sponsor and the underwriters have committed to purchase an aggregate of 7,000,000 private placement warrants (or 7,750,000 private placement warrants if the underwriters’ over -allotmentoption is exercised in full), each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per warrant, or $7,000,000 in the aggregate (or $7,750,000 if the underwriters’ over -allotmentoption is exercised in full), in a private placement that will close simultaneously with the closing of this offering. Of those 7,000,000 private placement warrants (or 7,750,000 private placement warrants if the underwriters’ over -allotmentoption is exercised in full), our sponsor has agreed to purchase 4,500,000 private placement warrants (or 4,875,000 private placement warrants if the underwriters’ over -allotmentoption is exercised in full) and the underwriters have agreed to purchase 2,500,000 private placement warrants (or 2,875,000 private placement warrants if the underwriters’ over -allotmentoption is exercised in full). The private placement warrants will also be worthless if we do not complete our initial business combination. This purchase will take place on a private placement basis simultaneously with the completion of our initial public offering. This issuance will be made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. No underwriting discounts or commissions were paid with respect to such sales. Item 16. Exhibits and Financial Statement Schedules. Exhibit Index

| Exhibit No. |     | Description                                                                                                                        |
| 1.1         |     | Form